SS
CARM

SBI Securities’s Carisma Therapeutics CARM Stock Holding History

SBI Securities’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-107
Closed -$29 – 4059
2025
Q3 		$29 Sell
107
-25
-19% -$8 ﹤0.01% 3839
2025
Q2 		$52 Sell
132
-1
-0.8% – ﹤0.01% 3710
2025
Q1 		$41 Buy
133
+102
+329% +$45 ﹤0.01% 3695
2024
Q4 		$13 Buy
+31
New +$26 ﹤0.01% 3895

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

SBI Securities's CARM Position: Q4 2025 in Review

SBI Securities sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 107 shares — an estimated $29 sold.

SBI Securities first reported a position in CARM in Q4 2024 and held it in 4 quarters. The position peaked at $52 in Q2 2025. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • SBI Securities reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • SBI Securities sold 107 Carisma Therapeutics shares in Q4 2025, an estimated $29.
  • SBI Securities first reported a position in Carisma Therapeutics in Q4 2024 and held it in 4 quarters.
  • SBI Securities's Carisma Therapeutics position peaked at $52 in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on SBI Securities's 13F filing for Q4 2025, filed 3 Feb 2026.